OK Biotech Co., Ltd. (4155.TW)
TWD 20.9
(-0.71%)
TWD 20.9
(-0.71%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 672.26 Million TWD | -44.66% |
| 2022 | 1.21 Billion TWD | 9.47% |
| 2021 | 1.1 Billion TWD | 39.43% |
| 2020 | 795.91 Million TWD | -13.34% |
| 2019 | 918.4 Million TWD | 57.6% |
| 2018 | 582.73 Million TWD | -14.06% |
| 2017 | 678.06 Million TWD | 23.14% |
| 2016 | 550.64 Million TWD | 11.16% |
| 2015 | 495.36 Million TWD | -11.72% |
| 2014 | 561.11 Million TWD | -33.75% |
| 2013 | 846.99 Million TWD | 160.1% |
| 2012 | 325.64 Million TWD | 77.65% |
| 2011 | 183.3 Million TWD | 93.76% |
| 2010 | 94.6 Million TWD | 13.41% |
| 2009 | 83.41 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 694.69 Million TWD | 3.34% |
| 2024 Q2 | 1.07 Billion TWD | 55.33% |
| 2023 Q4 | 672.26 Million TWD | -19.94% |
| 2023 Q2 | 817.84 Million TWD | -2.46% |
| 2023 Q3 | 839.7 Million TWD | 2.67% |
| 2023 FY | 672.26 Million TWD | -44.66% |
| 2023 Q1 | 838.43 Million TWD | -30.98% |
| 2022 Q4 | 1.21 Billion TWD | -2.51% |
| 2022 FY | 1.21 Billion TWD | 9.47% |
| 2022 Q1 | 1.02 Billion TWD | -7.41% |
| 2022 Q2 | 1.19 Billion TWD | 16.1% |
| 2022 Q3 | 1.24 Billion TWD | 4.45% |
| 2021 Q3 | 1.08 Billion TWD | -1.02% |
| 2021 Q4 | 1.1 Billion TWD | 2.72% |
| 2021 FY | 1.1 Billion TWD | 39.43% |
| 2021 Q1 | 920.03 Million TWD | 15.59% |
| 2021 Q2 | 1.09 Billion TWD | 18.63% |
| 2020 Q3 | 865.82 Million TWD | -11.3% |
| 2020 Q2 | 976.15 Million TWD | -6.34% |
| 2020 Q4 | 795.91 Million TWD | -8.07% |
| 2020 Q1 | 1.04 Billion TWD | 13.48% |
| 2020 FY | 795.91 Million TWD | -13.34% |
| 2019 Q3 | 819.68 Million TWD | 12.8% |
| 2019 Q4 | 918.4 Million TWD | 12.04% |
| 2019 Q1 | 574.95 Million TWD | -1.33% |
| 2019 Q2 | 726.65 Million TWD | 26.38% |
| 2019 FY | 918.4 Million TWD | 57.6% |
| 2018 Q2 | 791.05 Million TWD | 6.33% |
| 2018 FY | 582.73 Million TWD | -14.06% |
| 2018 Q1 | 743.95 Million TWD | 9.72% |
| 2018 Q4 | 582.73 Million TWD | 14.55% |
| 2018 Q3 | 508.69 Million TWD | -35.69% |
| 2017 FY | 678.06 Million TWD | 23.14% |
| 2017 Q4 | 678.06 Million TWD | 0.66% |
| 2017 Q3 | 673.62 Million TWD | -18.81% |
| 2017 Q2 | 829.72 Million TWD | 39.65% |
| 2017 Q1 | 594.15 Million TWD | 7.9% |
| 2016 Q4 | 550.64 Million TWD | 0.0% |
| 2016 Q1 | - TWD | -100.0% |
| 2016 FY | 550.64 Million TWD | 11.16% |
| 2016 Q2 | 655.52 Million TWD | 0.0% |
| 2015 Q1 | 538.25 Million TWD | -4.07% |
| 2015 Q3 | 495.36 Million TWD | -7.97% |
| 2015 Q2 | 538.25 Million TWD | 0.0% |
| 2015 FY | 495.36 Million TWD | -11.72% |
| 2015 Q4 | 495.36 Million TWD | 0.0% |
| 2014 Q1 | 697.58 Million TWD | -17.64% |
| 2014 FY | 561.11 Million TWD | -33.75% |
| 2014 Q4 | 561.11 Million TWD | 0.0% |
| 2014 Q3 | 561.11 Million TWD | -19.56% |
| 2014 Q2 | 697.58 Million TWD | 0.0% |
| 2013 Q1 | 725.16 Million TWD | 122.68% |
| 2013 Q2 | 725.16 Million TWD | 0.0% |
| 2013 FY | 846.99 Million TWD | 160.1% |
| 2013 Q4 | 846.99 Million TWD | 0.0% |
| 2013 Q3 | 846.99 Million TWD | 16.8% |
| 2012 Q4 | 325.64 Million TWD | -0.23% |
| 2012 Q2 | 232.14 Million TWD | 0.0% |
| 2012 Q3 | 326.41 Million TWD | 40.61% |
| 2012 FY | 325.64 Million TWD | 77.65% |
| 2011 FY | 183.3 Million TWD | 93.76% |
| 2011 Q2 | 110.22 Million TWD | 0.0% |
| 2011 Q4 | 183.3 Million TWD | 0.0% |
| 2010 FY | 94.6 Million TWD | 13.41% |
| 2010 Q4 | 94.6 Million TWD | 0.0% |
| 2009 FY | 83.41 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | 7.16 Billion TWD | 90.62% |
| Apex Medical Corp. | 883.97 Million TWD | 23.95% |
| Applied BioCode Corporation | 332.21 Million TWD | -102.357% |